Nanolattix T320 Anti-Cancer Drug Project Successfully Secured Listing and Received Tens of Millions in Funding Support from Taiyuan City
Release time:
2025-09-01
On August 26, 2025, the launch ceremony of the "Gathering Wisdom in Shanxi" Taiyuan Experts and Talents Summer Camp and the 2025 "Young Doctors Visit Taiyuan" event was grandly held in Taiyuan. At this conference, Nanolattix project "Research on Stable and Efficient Production Process and Clinical Trial Evaluation System for T320 Anti-Cancer Drug" was officially signed as a key "Unveiling and Assuming" initiative under Taiyuan’s key industrial chain program. The signing involved partnerships with WuXi Clinical, United-Power Pharma Tech Co., Ltd., Shanxi Cancer Hospital, and Shanxi Provincial People’s Hospital. The project received RMB 10 million in research funding support.
As an innovative anti-cancer drug independently developed by Na'an, T320 demonstrates significant clinical value and market potential. Preclinical studies have shown excellent anti-tumor activity and favorable safety profiles, indicating promising survival benefits for patients. Following this agreement, Na'an will proceed with Phase I clinical trials for T320 to systematically evaluate its tolerability in humans, characterize its pharmacokinetics, determine the maximum tolerated dose, and recommend an appropriate dosage for Phase II clinical trials. The study results will be used to submit a Phase I clinical trial report that meets the requirements of China’s National Medical Products Administration (NMPA), laying a solid foundation for subsequent registration applications.
This signing will accelerate the clinical development of T320, reflecting Taiyuan City’s strong support for innovation and key projects in Nanolattix biomedical industry. Nanolattix will continue to focus on critical aspects of anti-cancer drug clinical research, integrating resources from industry, academia, research, and medical institutions to expedite project progress. The company aims to provide high-quality and more accessible treatment options for patients as soon as possible, contributing scientific and technological strength to Shanxi Province’s goal of building a biomedical hub and fostering a broader health industry ecosystem.
Tag:
recommend News
Share
